Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

decadron

Home/Tag:decadron
9 04, 2012

The crazy world of “myeloma research speak”

Tags: , , , , , , , , , , , , , |0 Comments

Most of you probably know that I have been working on several new books about multiple myeloma.  My third book, New Myeloma Therapies from a Patient's Perspective, will be published and available by the end of this month.  Researching this book reminded me about how difficult it can be to understand "myeloma research speak."  It

23 10, 2011

I’m not going to let a few chemotherapy related side-effects slow me down!

Tags: , , , , , , , , |18 Comments

Consecutive M-spike nonoclonal protein readings of 0.5--and now 0.6--seem to confirm my autologous stem cell transplant failed to vanquish my multiple myeloma. So how did it feel, starting the same Revlimid/Velcade/dexamethasone chemotherapy cocktail I had endured for four, three week cycles prior to my transplant Wednesday? Physically, not so bad. The dexamethasone (Decadron) that is

26 01, 2011

Insightful Newspaper Article About Pomalidomide/Biaxin/Dex Clinical Study In New York City

Tags: , , , , |2 Comments

Here is an interesting article I found in the Cornell Daily Sun this morning.  Interesting because it is combines basics with a very insightful look at a promising clinical trial featuring pomalidomide:Weill Develops Alternative Cancer TreatmentJanuary 26, 2011 By Maria Minsker For patients suffering from cancer, learning their body is resistant to traditional therapy can

30 07, 2010

Link To Myeloma Beacon Story About Improving Survival Rates For Multiple Myeloma Patients

Tags: , , , , |3 Comments

Here is the first part of a story which ran Wednesday in The Myeloma Beacon:Higher Quality Response To Revlimid-Dexamethasone Combination Yields Better Prognosis For Relapsed And Refractory Multiple Myeloma PatientsBy Michelle Spektor - Published July 28, 2010A statistical analysis of two Phase 3 trials found relapsed and refractory multiple myeloma patients who achieved complete remission